Cellmid 2018 Annual Report
14
DIRECTORS’
REPORT
CONTINUED
Dr Martin Cross Director (Non-executive) Appointed 16 October 2017
Qualifications PhD, Microbiology, Aberdeen University Scotland, Fellow of the Australia Institute of Company
Directors
Experience Over 30 years’ experience working in the pharmaceutical and biotech industries primarily
in all aspects of marketing, selling and business management. This included global roles at
international Headquarters of AstraZeneca and Novartis. Former Country President for Novartis
Australia/NZ, Managing Director for Alphapharm (Mylan) Australia/NZ and Chairman of the
Generics Industry Association and Medicines Australia.
Interest in shares and options Shares: 175,000 indirectly held
Special responsibilities Member of the Audit and Risk Committee and member of the Nomination and Remuneration
Committee
Other directorships in listed Non-Executive Director Oncosil Ltd
entities held in the previous
three years
Other Non-Executive Director NHMRC National Institute of Dementia Research, Advisor Pursuit
Sports Pty Ltd, Advisor University of Technology Sydney (Pharmacy Commercial Advisory Board)
Mr Dennis Eck Director (Non-executive) Appointed 26 March 2018
Qualifications BSc, The University of Montana
Experience 40 years senior management experience in the retail sector, providing significant strategic and
operational expertise. Mr Eck, a professional investor, has extensive retail experience, from
fashion to groceries, including cosmetics and hair salons. As a senior strategist, Mr Eck has
helped reshape the operations of several retail businesses delivering outstanding shareholder
returns.
Interest in shares and options Shares: 5,331,579 directly held
Special responsibilities N/A
Other directorships in listed ULTA Inc.
entities held in the previous
three years
Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.